Castle Biosciences (CSTL) Q2 FY26 earnings call

Castle Biosciences delivered strong Q2 FY26 results, driven by robust growth in its core diagnostic tests, particularly TissueCypher, leading to a significant raise in full-year revenue guidance. Strategic investments in commercial resources and pipeline development are positioning the company for sustained long-term growth, despite some near-term pressure on melanoma volume and overall profitability. The company expects to achieve positive adjusted EBITDA for the remainder of 2026 and for the full year 2027.